Inhibition of both MAPK and PI3K/AKT pathways in colorectal cancer cells reduced clonogenic activity of CD133+ cells (a CSC marker) [34] while a selective PI3K inhibitor reduced in vivo tumour forming capacity of breast cancer cells [35]. This evidence concerns the gene PROM1 and breast cancer.